loading page…
loading page…
Full published JRCPTB Medical Oncology curriculum coverage, candidate-reported pitfalls and an AI-adaptive question bank by UK oncologists, mapped to the Federation assessment framework.
Full SCE Medical Oncology bank, AI Tutor and timed mocks — $29/month or $99/year. All paid exam banks included.
100 best-of-five SBAs · 3 hours · computer-based at Pearson VUE designated test centres
100 best-of-five SBAs · 3 hours · same day, after a 1-hour break · radiology, pathology and trial-data interpretation
Pitched at the level of a doctor approaching CCT in medical oncology — drug-pharmacology depth, trial design, biomarker-driven management
2026/01 sitting: 9 September 2026. Application window: 20 May–17 June 2026. Reasonable adjustment deadline: 25 June 2026. Results released approximately 6 weeks after the exam. From June 2026 sittings are delivered in centre.
Approximate question distribution across the JRCPTB Medical Oncology curriculum. Used to drive iatroX adaptive sequencing.
Source: official Federation of the Royal Colleges of Physicians of the UK blueprint
Mapped to the published JRCPTB curriculum and prioritised using item-density signals across the iatroX bank.
NSCLC driver mutations — EGFR (osimertinib first-line, ALK (lorlatinib, alectinib), ROS1, BRAF V600E, RET, KRAS G12C, MET ex14, HER2; testing pathways and resistance mutations (e.g. T790M obsolete, but C797S, MET amplification)
IO mechanism and irAE management — checkpoint inhibitor classes (PD-1, PD-L1, CTLA-4, LAG-3); irAE recognition (colitis, pneumonitis, hepatitis, hypophysitis, myocarditis); steroid sequencing per ESMO 2022/24 irAE guidelines
Breast cancer — HER2-low (T-DXd), HR+ early (adjuvant abemaciclib, ribociclib NATALEE), CDK4/6 in metastatic, TNBC (pembrolizumab + chemo in KEYNOTE-522), neoadjuvant strategies, OncotypeDx use
Prostate cancer — ARSI sequencing (abiraterone, enzalutamide, apalutamide, darolutamide), triplet therapy (PEACE-1, ARASENS), PARPi (olaparib BRCA-mutant) per PROfound, PSMA-RLT (lutetium-177)
Colorectal cancer — MSI testing, IO in dMMR (pembrolizumab KEYNOTE-177), RAS/BRAF testing, FOLFOXIRI vs FOLFIRINOX, encorafenib + cetuximab in BRAF V600E
Oncological emergencies — neutropenic sepsis bundles (MASCC score), TLS prevention and rasburicase, MSCC investigation and dexamethasone dosing, SVC obstruction, malignant hypercalcaemia
Trial design and biostatistics — non-inferiority trials, basket vs umbrella vs platform designs, hazard ratios and OS vs PFS endpoints, ITT vs per-protocol analysis
Survivorship — late toxicity (anthracycline cardiomyopathy, taxane neuropathy, IO endocrinopathies), second primary risk, fertility preservation discussions
Observations from UK medical oncology trainees and recent SCE candidates. Verify against current ESMO and NICE TA guidance.
Candidate-reported observations — not official guidance.
A pragmatic phased approach used by recent ST5–ST6 medical oncology passers.
A live item from the iatroX bank. Try it before launching a full session.
A researcher is designing a biomarker-stratified trial in NSCLC. Patients are randomised to treatment A or B, with stratification by PD-L1 status (≥50% vs <50%). The protocol specifies that if the overall population result is positive, the co-primary analysis will test PD-L1 ≥50% and PD-L1 <50% subgroups separately. What statistical design is this?
Why iatroX is built differently for SCE Medical Oncology.
Every iatroX item is tagged to a blueprint topic, so your performance dashboard mirrors the structure of the exam itself.
The engine surfaces your weakest topics first, in real time, instead of marching you through a static syllabus.
Incorrect items return at increasing intervals to interrupt the forgetting curve and lock knowledge into long-term memory.
Timed full-length simulations that mirror the official exam structure under realistic conditions.
One iatroX subscription includes the SCE Medical Oncology bank, the Socratic Tutor inside supported sessions, and every other premium iatroX exam bank.
Cancel anytime · 7-day money-back guarantee on annual
Over 1,000 best-of-five SBAs mapped to the published JRCPTB Medical Oncology curriculum and tumour-site distribution. Content is reviewed regularly against the current assessment framework.
Once yearly in September. The 2026 sitting is on 9 September 2026. Applications open 20 May 2026 and close 17 June 2026. Results are released approximately 6 weeks after the exam.
Two papers of 100 best-of-five SBAs each, three hours per paper, sat on the same day with a one-hour break between. Total 200 questions. From June 2026 all sittings are in-centre at Pearson VUE locations. Paper 2 is widely reported to include more radiology, pathology and trial-data interpretation items.
Most UK trainees sit during ST5 or ST6 (penultimate year of higher specialty training). There are no formal restrictions on when in training you sit, but CCT requires a pass before completion. International candidates can sit at any time once registered with the Federation.
UK fee is £700; international fee is £875. Fees are non-refundable after the application closing date. From June 2026 all sittings are delivered in-centre at Pearson VUE locations.
The SCE is the UK-mandated Federation knowledge assessment for CCT in Medical Oncology. ESMO offers its own examinations (ESMO Examination in Medical Oncology) which are not mandatory for UK CCT but are valuable for European recognition. iatroX content is mapped to both UK and ESMO standards.
Yes. A single iatroX subscription (£29/month or £99/year for UK users; $29/$99 elsewhere) includes the SCE Medical Oncology bank alongside every other premium iatroX exam bank. No add-ons or per-exam fees.
Other iatroX hubs you may find useful.
see how iatroX compares to PassMedicine, Quesmed.
Reviewed by Dr Kola Tytler MBBS CertHE MBA MSt MRCGP · Last reviewed 12 May 2026
See our methodology and editorial policy.